Welcome: Guest | Site Use Options | Register | Login |

Paganini Biopharma Inc

Paganini Biopharma Inc

Profile last edited on: 4/30/2019
17328 Ventura Boulevard Suite 147
Encino, CA 91316
  (818) 784-5527
Business Identifier: MAb against the target in development for triple-negative breast cancer
Public Profile:
Spun out of UCLA, Paganini Biopharma, Inc. had been a development stage biotechnology company focused on therapeutics for cancer. The firm was acquired in 2017 by OncoResponses. Paganini's first product had been a unique human monoclonal antibody that targets breast cancer stem cells and was being developed for triple negative breast cancer. Paganinis lead drug, ONCR-201 - a monoclonal antibody developed to target epithelial membrane protein 2, a protein shown in research to have a role in ovarian cancer. OncoResponse was itself only founded in 2015 - having been launched as a firm when Theraclone - a Seattle biotech company -and the University of Texas M.D. Anderson Cancer Center announced the formation of a new company seeking to find personalized antibodies that c/would help fight cancer.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Targeting Breast Cancer Stem Cells with PG-101

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options


Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920